FFL Flash Alert - On a struggling Dallas Cowboys, will a struggling Ezekiel Elliott be able to turn things around against a very good Pittsburgh run defense?
FFL Flash Alert - On a struggling Dallas Cowboys, will a struggling Ezekiel Elliott be able to turn things around against a very good Pittsburgh run defense?
Japan plans to temporarily cut its aviation fuel tax by 80% at most to help the airline industry, which is struggling with the impact of the coronavirus pandemic, the Kyodo news agency reported on Tuesday.
SAN ANTONIO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rackspace Technology™ (NASDAQ: RXT) (the “Company”) today announced the early tender results for its previously announced tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 8.625% Senior Notes due 2024 (the “Notes”). The Tender Offer is subject to the terms and conditions set forth in the Offer to Purchase, dated November 16, 2020, relating thereto (the “Offer to Purchase”). As of the previously announced early tender deadline of 5:00 p.m., New York City time, on Monday, November 30, 2020 (the “Early Tender Time”), the Company has been advised by Global Bondholder Services Corporation, as Depositary for the Tender Offer, that $259,147,000 in aggregate principal amount, or approximately 49.91%, of the outstanding Notes had been validly tendered and not withdrawn in the Tender Offer. The withdrawal deadline relating to the Tender Offer occurred at 5:00 p.m., New York City time, on Monday, November 30, 2020. Notes previously tendered and not withdrawn and Notes that are tendered after the withdrawal deadline may not be withdrawn, except as required by law. The Tender Offer is scheduled to expire at 12:00 midnight, New York City time, on Monday, December 14, 2020 (the “Expiration Time”), unless extended or terminated earlier.Subject to the terms and conditions of the Tender Offer, the Company is accepting for purchase all Notes validly tendered and not validly withdrawn prior to the Early Tender Time, with the settlement date for such purchase expected to occur on or about December 1, 2020.Citigroup Global Markets Inc. is acting as the dealer manager (the “Dealer Manager”) for the Tender Offer. Global Bondholder Services Corporation is acting as the Depositary and the Information Agent for the Tender Offer. Questions regarding the Tender Offer should be directed to Citigroup Global Markets Inc. at (800) 558-3745 (toll-free) or (212) 723-6106 (collect). Requests for documentation should be directed to Global Bondholder Services Corporation at (212) 430-3774 (for banks and brokers) or (866) 470-3900 (for all others).This announcement is for informational purposes only. This announcement is not an offer to purchase or a solicitation of an offer to purchase the Notes. The Tender Offer is being made solely pursuant to the Offer to Purchase. The Tender Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Tender Offer to be made by a licensed broker or dealer, the Tender Offer will be deemed to be made on behalf of the Company by the Dealer Manager, or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.None of the Company or its affiliates, the Dealer Manager, the Depositary, the Information Agent or the trustee with respect to the Notes is making any recommendation as to whether holders should tender any Notes in the Tender Offer, and neither the Company nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender.About Rackspace Technology Rackspace Technology is a leading end-to-end multicloud technology services company. We design, build and operate our customers’ cloud environments across all major technology platforms, irrespective of technology stack or deployment model. We partner with our customers at every stage of their cloud journey, enabling them to modernize applications, build new products and adopt innovative technologies.Rackspace Technology Safe Harbor StatementSome of the statements in this news release constitute “forward-looking statements” that do not directly or exclusively relate to historical facts. The forward-looking statements made in this release reflect the Company’s intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control. Known risks include, among others, the risks included in Rackspace Technology, Inc.’s filings with the U.S. Securities and Exchange Commission. Because actual results could differ materially from the Company’s intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained in this press release with caution. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.IR ContactJoe Crivelli Rackspace Technology Investor Relations IR@rackspace.comPR ContactNatalie Silva Rackspace Technology Corporate Communications firstname.lastname@example.org
The video conferencing specialist's stock has surged more than 562% so far in 2020, so even the latest quarter's stellar results weren't enough to keep the stock from slipping.
The British empire that owns Topshop, Topman and several other brands is seeking a new buyer.
Mainland China reported 12 new COVID-19 cases on Nov. 30, down from 18 cases a day earlier, the country's national health authority said on Tuesday. The National Health Commission said in a statement eight of the new cases were imported infections originating from overseas. The number of new asymptomatic cases, which China does not classify as confirmed cases, fell to five from 17 cases a day earlier.
Dick Johnson Racing boss Ryan Story has been named Chair of the Australian Motor Racing Commission.
NJR earnings call for the period ending September 30, 2020.
Increase in women population, penetration of Korean culture in Malaysia, and surge in women working population drive the growth of the Malaysia skin care market. The supermarket/hypermarket segment dominated the market in 2019, accounting for nearly one-third of the market. Moreover, lack of raw materials for the manufacturing of luxury cosmetics and the disrupted supply chain have created a shortage of supply of cosmetics.portland, OR, Nov. 30, 2020 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the Malaysia skin care market was pegged at$804.5 million in 2019, and is anticipated to garner $1.28 billion by 2027, growing at a CAGR of 8.1% from 2021 to 2027.Increase in women population, penetration of Korean culture in Malaysia, and surge in women working population drive the growth of the Malaysia skin care market. However, high price sensitivity and Halal consumerism hamper the market growth. On the contrary, increase in demand for skincare products with safe & sustainable ingredients and surge in penetration of digital technology are expected to create lucrative opportunities for the market players in the future.In-depth analysis of the COVID-19 impact on the Malaysia skin care Market@ https://www.alliedmarketresearch.com/request-for-customization/7012?reqfor=covidCovid-19 scenario: * To curb the spread of the Covid-19 virus, governments of several countries have banned international travel and imposed restrictions on imports and export. * Since the Covid-19 pandemic, the retail business is closed and the beauty, personal care, and cosmetic sectors are severely affected. * Moreover, lack of raw materials for the manufacturing of luxury cosmetics and the disrupted supply chain have created a shortage of supply of cosmetics. The Malaysia skin care market is segmented on the basis of type, demographics, age group, and distribution channel.Based on type, the market is categorized into cream, lotion, and others. The cream segment held the largest share in 2019, accounting for more than half of the market. However, the lotions segment is estimated to register the highest CAGR of 8.9% during the forecast period.Download Sample Copy Of Report@ https://www.alliedmarketresearch.com/request-sample/7012On the basis of demographics, the market is classified into male and female. The female segment held the largest share in 2019, contributing to nearly three-fifths of the market. However, the male segment is estimated to manifest the highest CAGR of 9.23% from 2020 to 2027.Based on age group, the market is divided into supermarket/hypermarket, specialty stores, department stores, beauty salons, pharmacies & drug stores, and online sales channels. The supermarket/hypermarketsegment dominated the market in 2019, accounting for nearly one-third of the market. However, the online sales channel segment is anticipated to register the highest CAGR of 10.61% during the forecast period.Send me enquire HEre@ https://www.alliedmarketresearch.com/purchase-enquiry/7012The Malaysia skin care market report includes an in-depth analysis of the major market players such as the Procter & Gamble Company, L'Oréal Group, Bejesdorf AG, Unilever PLC,Estee Lauder Companies Inc., Berjaya Corporation Berhad, Wipro Ltd., Alticor Inc., Shiseido Company Limited, and Avon Products Inc.Avenue Basic Plan | Library Access | 1 Year Subscription | Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starterGet more information: https://www.alliedmarketresearch.com/library-accessAbout Us:Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. CONTACT: Contact: David Correa 5933 NE Win Sivers Drive 205, Portland, OR 97220 United States Toll Free (USA/Canada): +1-800-792-5285, +1-503-446-1141 International: +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 email@example.com Web: https://www.alliedmarketresearch.com Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research/
The global polypropylene market size was surpassed at US 114.77 bn in 2019 and expected to rake USD 173.49 bn by 2027, with a CAGR of 5.3% from 2020 to 2027.OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- In 2019, the global volume of polypropylene market stood at nearly 72.03 Million Tons and expected to register a growth rate of nearly 4.5% over the forecast period. Polypropylene is basically a thermoplastic material that is prominently used for manufacturing fibers and molded materials. It provides excellent chemical and mechanical resistance coupled with translucent features. Excellent stiffness, lightweight, and flexibility properties offered by the product are the major trends and are significantly promoting the market growth over the upcoming years. In addition to these factors, they are notably used in various end-use industries such as automotive, agriculture, packaging, construction, electrical & electronics, and many others.Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1153Growth FactorsIncreasing demand of polypropylene from various end-use sectors such as automotive, packaging, healthcare, building & construction, and electrical & electronics attributed as the primary factors that drives the growth of the product. Features of polypropylene such as low-cost and excellent mechanical strength along with moldability are the major factors due to which more than half of the plastics used in the automotive sector are polypropylene. Polypropylene is used in various parts of an automobile, such as instrumental panels, bumpers, and door trims.Furthermore, the properties of polypropylene that include lightweight, low density, durability, high heat resistance, and high clarity make it a suitable for packaging applications. Polypropylene is also used significantly in the electrical & electronics and building & construction for the insulation of building wrap as well as electronics goods.However, rising environmental concern and government regulations for banning the use of plastic products expected to hamper the market growth in the upcoming years. Furthermore, there are number of substitutes available for the polypropylene such as polyethylene terephthalate (PET), polyethylene (PE), polyvinyl chloride (PVC), and many other that again restricts the market growth in the coming years.View full Report with Complete ToC@ https://www.precedenceresearch.com/polypropylene-marketRegional SnapshotsThe Asia Pacific captured major share in the market revenue accounting for nearly half of the market value in 2019 and further expected to growth prominently throughout the forecast timeframe. The remarkable growth of the region is mainly attributed to the increasing demand of polypropylene from packaging, automotive, medical, and building & construction sectors. The region is a growing market place for all the aforementioned industries owing to large consumer base and high growth in the disposable income of consumers that in turn attributed as a prime factor for the market growth for polypropylene in the region. In addition to this, supportive government policies for light weight electronics and automotive parts in order to control the rising environmental pollution again boost the demand for the product over the upcoming period.Moreover, North America and Europe are the prominent regions that hold nearly 30-35%market value collectively in the year 2019. Growing packaging and automotive industry in the regions are the main factors supporting the rapid growth of the market in the regions. Rising trend for packaged foods and drinks because of hectic lifestyle again triggers the growth of the polypropylene packaging solutions in these regions.Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1153Key Players & StrategiesThe global industry for polypropylene witnesses intense competition among the market players owing to the presence of large number of small and medium sized players. Furthermore, these industry participants are significantly involved in the forward integration of value chain process that results in the continuous supply of raw materials as well as this reduces the overall manufacturing cost. In addition to forward integration, the market players also invest prominently in the research & development (R&D) sector to excel their product specification coupled with the market reach.Some of the key players operating in the market are Lyondellbasell Industries Holdings B.V., Exxon Mobil Corporation, SABIC, China Petrochemical Corporation, Eastman Chemical Company, BASF SE, LG Chem, Trinseo S.A., Total S.A, and Westlake Chemical Corporation among others.Report Highlights * The Asia Pacific emerged as the market leader and accounted for a revenue share of approximately 50% in the year 2019 due to growing demand for polypropylene from packaging and automotive sectors * North America accounted for a value share of 16% in 2019 owing to its rising application for packaging in the food & beverage industry * By type, homopolymer dominated the global polypropylene market and accounted for around 83% revenue share in the year 2019 * Increasing demand for copolymer polypropylene in medical sector because of its toughness at low temperature along with higher stress crack resistance expected to drive its demand * Based on process, injection molding dominated the global market with a revenue share of around 37% in 2019 * Film & sheet accounted for the highest revenue share of nearly 36% in the global market in 2019 owing to its rising demand in boxes, binders, packaging materials, and portfolios * Fiber estimated to be the second largest application segment accounting for a value share of around 30% in 2019 because of rising demand from automotive industry Market SegmentationBy Process * Blow Molding * Extrusion * Injection Molding * OthersBy Type * Copolymer * HomopolymerBy Application * Film & Sheet * Raffia * Fiber * OthersBy End-use * Building & Construction * Electrical & Electronics * Automotive * Medical * Packaging * OthersBy Regional * North America * U.S. * Canada * Europe * U.K. * Germany * France * Asia Pacific * China * India * Japan * South Korea * Rest of the World Full Report is Ready | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1153You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 774 402 6168About UsPrecedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.For Latest Update Follow Us:https://www.linkedin.com/company/precedence-research/
HALIFAX, Nova Scotia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2019. Profit and Loss Highlights * Revenue: The Company recorded revenues in FY2020 of $919,072 compared to $527,445 in FY2019. The increase in revenue was due to the Company’s additional revenues generated with the REVEALCOVID-19TM Total Antibody Test. * Gross Profit: The Company recorded a gross profit in FY2020 of $572,280 compared to $423,351 for the same period last year. * Operating expenses: In this financial year, the Company recorded operating expenses of $1,872,437 compared to $1,719,384 in FY2019. The increase of 9% in operating expenses were due to additional labour costs associated with the enhanced production for the Company’s REVEALCOVID-19TM Total Antibody Test. * Net loss: The Company recorded a net loss of $2,045,386 compared to $2,106,448 in FY2019.Balance Sheet Highlights * Assets: The Company had an expected increase of its assets by $3,143,557 compared to last financial year which was mainly due to the adoption of IFRS 16 which accounts for approximately $2.3m. IFRS 16, which was adopted by the Company in August 2019, changes the accounting requirement of how to recognize, measure, present and disclose leases. For MedMira, its leases are placed into assets and liabilities. * Liabilities: The Company’s liabilities increased by $5,188,943 or 38% between FY2019 and FY2020. This was mainly due to the adoption of IFRS 16 of approximately $2.3m. Furthermore, prepayments received from customers during this period in the amount of approximately $1.2m are considered deferred revenue and part of the current liabilities until these have been converted into revenue. * Loans in default slightly increased by $13,850 or 1% compared to the previous financial year. This increase was due to a related party’s loan being due in FY2020. All long and short terms debts are currently under negotiation to restructure terms and conditions of repayment. * Working Capital deficit: As a result of the increases noted above, the Company recorded higher working capital deficit of $1,371,642 or 10% compared to last financial year which was mainly due to an increase in deferred revenue (prepayment) of $1,240,890 from the Company’s distributors. These prepayments will be converted into revenue at the time of shipment.“In FY2020, MedMira was able to highlight the company’s adaptability to new global changes by developing a high-quality testing solution within a short time and which through repeated third-party testing demonstrated accuracy and ease of use. In addition, the company successfully ramped-up production to unprecedented levels without sacrificing stringent quality control measures,” said Markus Meile, CFO of MedMira Inc. “Whereas this new opportunity provided MedMira additional revenues and cash flow, other product sales had suffered during the third and fourth financial quarters, which was mainly due to the global lock downs and the market’s focus on COVID-19 testing. However, subsequent to the financial year end, these sales have steadily increased and will be reported in the following financial quarters.”Regulatory Status MedMira has applied to the US FDA to obtain FDA Emergency Use Authorization (EUA) for the REVEALCOVID-19™ Total Antibody Test, and its applications is under review. However, while awaiting the authorization, REVEALCOVID-19™ Total Antibody Test can be distributed in the U.S. according to Section IV.D of the Policy for Coronavirus Disease-2019 Test. In addition, MedMira received on the 21st of May 2020 the right to sell in all countries accepting CE mark. In Canada, the Company has re-submitted, based on the new template issued by Health Canada, its application on the 29th of October 2020. No sales can be made in Canada prior to receipt of the interim order from Health Canada.The Company’s financial statements and management’s discussion and analysis are available on the Company’s profile on SEDAR at www.sedar.com. For matters of going concern, reference is made to the Auditor’s Emphasis of Matter statement in the fiscal year ended 2020 Auditors Report and note 2b in the audited financial statements which are also available on SEDAR.About MedMiraMedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company’s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.MedMira Contacts:Markus Meile, CFO Tel: 902-450-1588 Email: email@example.com
Liberty star Sabrina Ionescu shared a video of her getting shots up in the gym on Monday, and appears back to normal after undergoing ankle surgeryr.
Andrew Bogut has taken to his new podcast to announce his immediate retirement from basketball.
Asian stock markets faced a choppy session on Tuesday after Wall Street dipped as investors took profits at the end of a record-breaking month while still remaining upbeat about the prospect of a COVID-19 vaccine fuelling gains into next year. "U.S. markets were a little bit lower, that's what was holding us back a little bit," said Chris Weston, head of research at Melbourne brokerage Pepperstone. Hong Kong's Hang Seng index futures were down 0.36%.
The couple were married in front of friends in a traditional ceremony.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cluny Capital Corp. (the “Company” or “Cluny”) (TSXV:CLN.H), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the “Exchange”), is pleased to provide further details on its previously announced definitive agreement entered into on November 3, 2020 (the “Agreement”) with Teonan Biomedical Inc. ("Teonan") for the proposed combination of the two companies (the “Proposed Transaction”). The Proposed Transaction is intended to constitute the Company’s Qualifying Transaction (as defined by Policy 2.4 of the Exchange) and would result in a reverse takeover of the Company by Teonan. As the Proposed Transaction is not a “Non-Arm’s Length Qualifying Transaction” (as such term is defined by the Exchange) the approval of the shareholders of the Company is not required for the Proposed Transaction; however, certain ancillary matters described below will require the approval of shareholders of the Company. Subject to certain conditions set out in the Agreement, Teonan will amalgamate with a wholly-owned subsidiary of the Company in order to facilitate the completion of the Proposed Transaction. The full details of the Proposed Transaction will be included in the filing statement to be submitted in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, it is the intention of the parties that the Company (the Company after the Proposed Transaction being referred to herein as the “Resulting Issuer”) will continue to carry on the business of Teonan and will be listed as a Tier 2 life sciences issuer on the Exchange. About TeonanTeonan is a privately held arm’s length company incorporated under the Canada Business Corporations Act (the “CBCA”) on October 30, 2014 with its headquarters in the Province of Quebec. Teonan produces instant wellness beverages under its two brands, Teonan and Velada. Inspired by the relationships ancient cultures held with functional mushrooms and in line with growing consumer trends towards functional foods, with the functional mushroom market poised to grow annually by 9% for the next three years, and expected to reach US$34B by 20241, Teonan created two lines of instant beverages that offer both delicious flavours and immune support through a custom blend of organic functional mushroom extracts. Offered in a variety of flavours, the instant beverage mixes are all probiotic, certified organic (Ecocert - USDA), vegan, dairy free, GMO free and gluten free. In December of 2019, Teonan began direct to consumers sales in North America via its online stores and sales to July 2020 reached $196,918 with a limited marketing budget. Teonan’s short term marketing goals include the launch of a retail initiative to diversify its sales channels and market exposure, brand reinforcement, the revamping and optimization of its website to increase e-commerce flow-through, return on ad spend rates and increase organic traffic. In addition, Teonan anticipates adding two new non-caffeinated beverages flavours to its product line, following client demand. Under it’s Velada brand, Teonan has begun production of cannabidiol (CBD) infused beverages having the same high-quality ingredients and attributes of the Teonan beverages. The Velada beverages are produced at its facility in Quebec, in accordance with its micro-processing license (the “License”) granted in November of 2019 by Health Canada. Pursuant to recent amendments to the Cannabis Regulations that came into force on October 17, 2019, Teonan has filed for an amendment to its License with Health Canada that would enable to it to sell its edible products to provincial and territorial authorized resellers. Teonan anticipates receiving the amendment to its License in Spring 2021. The cannabis beverage market in Canada alone is estimated to be worth $529M2 and with relatively few established suppliers and a high barrier to entry, Teonan expects its offering within the beverage category at a competitive price point will allow it to capture a share of the market. 1 Mondor Intelligence: FUNCTIONAL MUSHROOM MARKET - GROWTH, TRENDS, AND FORECAST (2020 - 2025) (https://www.mordorintelligence.com/industry-reports/functional-mushroom-market) 2 Press release (June 3, 2019) Deloitte estimates next round of cannabis legalization will create a new $2.7-billion market in Canada (https://www2.deloitte.com/ca/en/pages/press-releases/articles/cannabis-legalization.html)Selected Financial Information The following table sets out selected financial information of Teonan for the periods, and as of the dates, indicated. The selected financial information has been derived from the unaudited financial statements for the year-ended July 31, 2019 and the audited financial statements for the year ended July 31, 2020:Financial PositionAs at July 31, 2020 (CA$)As at July 31, 2019 (CA$)As at July 31, 2018 (CA$) Current Assets699,901177,75292,274 Total Assets728,543207,94392,274 Current Liabilities152,063453,645155,713 Total Liabilities826,063(1)453,645155,713 Total Shareholder’s Equity(97,520)(245,702)(63,439) Income Statement Total Revenues196,918-- Gross Margin147,770-- Net Loss(419,589)(182,263)(63,539) Notes: (1) Includes the Teonan Convertible Debentures (as defined below) outstanding, in the principal amount of $690,000, at such date.The Proposed TransactionOn or immediately prior to the completion of the Proposed Transaction, and subject to the approval of Cluny’s shareholders; (i) Cluny will change its name to “The Good Shroom Co Inc.” (Les bons Champignons inc) or such other name as Teonan may decide (the “Name Change”); (ii) Cluny will be continued from an Ontario corporation to a corporation under the CBCA (the “Continuation”); and (iii) Cluny will consolidate its common shares on the basis of one (1) post consolidation common share of Cluny for each three (3) pre-consolidation common shares of Cluny (the “Consolidation”). There are 14,692,235 common shares of Cluny outstanding as of the date hereof.Pursuant to the amalgamation and in exchange for their Teonan shares, the existing shareholders of Teonan will receive 25,000,000 post-Consolidation common shares of Cluny (each a “Resulting Issuer Share”) at a deemed post-Consolidation price of $0.25 per Resulting Issuer Share, pro rata to their holdings. In addition to the foregoing: (i) up to 3,000,000 Resulting Issuer Shares shall be issuable to Mr. Scott Jardin, the Chief Financial Officer of Teonan, in connection with the Proposed Transaction provided certain performance milestones are met, pursuant to an agreement entered into between Teonan and Mr. Scott Jardin on September 1, 2020 (the “Performance Shares Agreement”); and, (ii) up to a maximum of 5,439,562 Resulting Issuer Shares will be issued pursuant to the conversion of certain outstanding convertible debentures of Teonan (the “Teonan Convertible Debentures”) having an aggregate principal value of $975,000 along with the unpaid accrued interest up to the closing date of the Proposed Transaction (such maximum assumes the closing date of the Proposed Transaction is on or before February 28, 2021). The Resulting Issuer Shares to be issued in connection with the Proposed Transaction shall be issued pursuant to the provisions of section 2.11(b) of National Instrument 45-106 - Prospectus Exemptions.Pursuant to the Performance Shares Agreement and the Agreement: (i) 1,000,000 Resulting Issuer Shares shall be issued upon the receipt of all applicable authorizations, licenses and other legal requirements, including the License amendment discussed above, for the commercialization of cannabis related products; (ii) 1,000,000 Resulting Issuer Shares shall be issued upon Teonan reaching gross sales of $750,000, for its cannabis related products within a 12-month period following receipt of the amended License; and (iii) 1,000,000 Resulting Issuer Shares shall be issued if gross sales reach $2,500,000 in cannabis related products in the 12 months that follow receipt of the amended License. In the event one or more of the foregoing milestones are met prior to the closing date of the Proposed Transaction, the relevant number of Resulting Issuer Shares shall be issued on closing.The Proposed Transaction is subject to a number of conditions precedent, including, without limitation: (i) receipt of all applicable regulatory, shareholder and third party approvals, including approval of the Exchange for the Proposed Transaction; (ii) completion of the Continuation, Consolidation and Name Change; (iii) the listing of the Resulting Issuer Shares on the Exchange; and (iv) completion of the Offering (as defined below).A Finder’s Fee of 1,400,000 Resulting Issuer Shares is payable to an arm’s length party in connection with the closing of the Proposed Transaction.Cluny and Teonan will be requesting a waiver from the Sponsorship requirement as per the Exchange policies; however, there can be no assurances at this time that such waiver will be granted.The Concurrent OfferingConcurrent with the closing of the Proposed Transaction, the Company intends to conduct a brokered offering (the “Offering”) of subscription receipts (the “Subscription Receipts”) at a price of $0.25 per Subscription Receipt for minimum gross proceeds of $1,500,000 and maximum gross proceeds of $2,875,000. For such purpose, a letter of intent has been entered into with Leede Jones Gable Inc. (the “Agent”) who will be the lead agent and book-runner for the Offering.The gross proceeds of the Offering, less certain expenses of the Agent (such proceeds, the “Escrowed Funds”), will be deposited in escrow at closing of the Offering with an escrow agent mutually acceptable to the Company and the Agent (the “Escrow Agent”). The Escrowed Funds (less amounts payable by the Company to the Agent, including the Cash Commission (as defined below)) will be released from escrow by the Escrow Agent to the Company upon the completion or irrevocable waiver or satisfaction of certain conditions, including the condition that all conditions precedent to the Proposed Transaction provided for in the Agreement and as may be required by the Exchange have been satisfied (together, the “Escrow Release Conditions”).In the event that the Escrow Release Conditions are not satisfied or are incapable of being satisfied on or before April 15, 2021, the Escrowed Funds, as well as any accrued interest earned thereon (less any applicable withholding taxes), will be returned to purchasers of the Subscription Receipts, which will then be cancelled.Upon the satisfaction of the Escrow Release Conditions, each Subscription Receipt shall be automatically exchanged, without any further act or formality or payment of any additional consideration and subject to adjustment, for one common share in the capital of the Resulting Issuer and one common share purchase warrant of the Resulting Issuer (each, a “Resulting Issuer Warrant”). Each Resulting Issuer Warrant shall be exercisable to acquire one Resulting Issuer Share at an exercise price of $0.50 for a period of 24 months from the closing of the Offering. The Resulting Issuer Warrants may be subject to an accelerated expiry at the discretion of the Resulting Issuer if the volume weighted average closing price of the Resulting Issuer Shares is greater than $0.60 for a period of 10 consecutive trading days on the Exchange. Upon completion of the Offering, a minimum of 6,000,000 and a maximum of 11,500,000 Subscription Receipts will be issued.The Agent will receive a cash commission equal to 8% of the gross proceeds of the Offering (the “Cash Commission”), provided that the Cash Commission payable on the gross proceeds raised in respect of investors introduced to the Offering directly by the Corporation shall be equal to 3.0% of such gross proceeds (subject to a maximum of $750,000 in such gross proceeds). The Cash Commission shall be deposited into escrow on the closing date of the Offering and shall be released (together with interest earned thereon) upon satisfaction of the Escrow Release Conditions and the release of the Escrowed Funds. In addition, the Resulting Issuer shall issue the Agent upon completion of the Proposed Transaction such number of non-transferable compensation options (each a “Compensation Option”) as is equal to 8% of the number of Subscription Receipts purchased under the Offering. Each Compensation Option is exercisable for one Resulting Issuer Share at a price of $0.25 per Resulting Issuer Share for a period of 24 months from the closing date of the Offering.The proceeds of the Offering will be used for general working capital. All securities issued pursuant to the Offering will be subject to a four-month resale restriction from the date of issuance of the Subscription Receipts.The Resulting IssuerProposed Management and Board of Directors of the Resulting IssuerUpon completion of the Proposed Transaction, it is anticipated that the persons identified below will serve as directors and officers of the Resulting Issuer, subject to acceptance by the Exchange.Mr. Eric Ronsse, the founder of Teonan who will serve as CEO and a director of the Resulting Issuer, is an accomplished entrepreneur with particular expertise in CPGs (consumer packaged goods), namely in the functional food space, who strives to build brand affinity through honest and sustainable corporate practices. He has over a decade of executive leadership and management experience in food distribution, third party logistics and the functional beverage space, during which time he grew Cargologan Inc., a private logistics company, from a operational footprint of 28,000 square feet to 255,000 square feet. Eric also co-founded Hasaji, a food snack CPG company with products distributed in over 400 outlets in Asia, primarily in Mongolia.Mr. Scott Jardin, who will serve as Chief Financial Officer of the Resulting Issuer, is an accounting professional providing consulting services to companies with a focus on operations setup and efficiency. Mr. Jardin has over 10 years of experience as a CPA, CGA and is the former CEO of AAA Montreal, a cannabis company with an Industrial Hemp License. He was an Associate Director of Cancer & Genetics Research Centres at McGill University and was also an Associate Director, Internal Audit at McGill UniversityMr. Stephanus Rossouw, who is currently the Chief Marketing officer of Teonan and its co-founder, will serve in the same role with the Resulting Issuer and join the board of directors. Mr. Rossouw holds a MSc in Plant Science from McGill University and has over ten years of practical and theoretical experience in nutraceutical product development and phytochemistry and practical expertise in branding, digital marketing and establishing e-commerce strategies.Mr. Frank Aton is expected to join the board of directors of the Resulting Issuer as an independent director. Formerly Vice President, Human Resources at Merck and Co., Mr. Aton has over 25 years experience in executive leadership and operations. His vast experience acquired in large global organizations such as General Electric, Merck & Co, in various geographical areas, namely the United States, Europe, Middle East, Africa and Canada has allowed him to build a worldwide network of pharma and other industry executives.Mr. Claude Dufresne is also expected to join the board of directors of the Resulting Issuer as an independent director. He is a professional engineer, member of l’Ordre des Ingénieurs du Québec and, is currently President and CEO of NioBay Metals, an Exchange listed company, and serves on its board. As a 30-year veteran of the mining industry, he has held various marketing positions with both Iamgold and Cambior in the past and started his own firm, Camet Metallurgy Inc., which trades various metals commodities. He is an active investor and is experienced in environmental, social & governance (ESG) issues.Mr. Steve Saviuk, who will also join the board of directors of the Resulting Issuer as an independent director, is a CPA, CA who started his career in accounting at KPMG, and moved to venture capital investing through Manitex Capital Inc., a company he co-founded over 30 years ago, and that actively invests in emerging companies with a focus on the life science, renewable energy and sustainable resource sectors. He also co-founded Valeo Pharma in 2003 and has since served as its president and CEO. Mr. Saviuk transformed Valeo Pharma, from its early years as an in-licensor of established brands to a fast-growing full service Canadian pharmaceutical company and instrumented the recent sale of certain assets to Valeant Canada. Mr. Saviuk also has extensive experience with executive management and corporate governance, which he acquired while serving on various board of both public and private companies.VendorsThe controlling shareholders of Teonan are Mr. Eric Ronsse, who resides in the municipality of Kirkland (Quebec) and holds a 71.4% equity interest in Teonan and Mr. Stephanus Rossouw who resides in the municipality of Ile Perrot (Quebec) and holds a 23% interest.Structure Upon completion of the Proposed Transaction, assuming completion of the minimum Offering, it is anticipated that, on an undiluted basis, the current shareholders of Cluny will hold 11.46% of the Resulting Issuer Shares, the current shareholders of Teonan will hold 58.50% of the Resulting Issuer Shares, the holders of the Teonan Convertible Debentures will hold 12.73% of the Resulting Issuer Shares and the subscribers in the Offering will hold 14.04% of the Resulting Issuer Shares. Assuming completion of the maximum Offering, it is anticipated that, on an undiluted basis, the current shareholders of Cluny will hold 10.15% of the Resulting Issuer Shares, the current shareholders of Teonan will hold 51.83% of the Resulting Issuer Shares, the holders of the Teonan Convertible Debentures will hold 11.28% of the Resulting Issuer Shares and the subscribers in the Offering will hold 23.84% of the Resulting Issuer Shares.For further information:Cluny Capital Corp. Michael Frank, Chief Executive Officer (416) 369-5265 firstname.lastname@example.org Teonan Biomedical Inc. Erin Ronsse, President email@example.comThe information provided in this news release regarding Teonan and the Resulting Issuer has been provided by Teonan and has not been independently verified by the Company.Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.Cautionary Statement Regarding Forward Looking Information This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the terms of the Proposed Transaction and Teonan’s business operations and prospects. Cluny and Teonan made certain material assumptions, including but not limited to: prevailing market conditions; general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of the Teonan to execute and achieve its business objectives, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to: adverse market conditions; the inability of Cluny or Teonan to complete the Proposed Transaction on the terms disclosed in this news release, or at all; the inability of Cluny to complete the Offering; reliance on key and qualified personnel; regulatory and other risks associated with the cannabis industry in general, including changes to the Cannabis Act and related legislation, the reinstatement or continuance of government confinement measures and other measures related to the COVID-19 pandemic, as well as those risk factors discussed or referred to in disclosure documents filed by Cluny with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. The foregoing list of material risk factors and assumptions is not exhaustive. Should any factor affect Cluny in an unexpected manner, or should assumptions underlying the forward looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Cluny does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this news release is made as of the date of this news release and Cluny undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.
Thirty Sydney councils will plant 40,000 trees as part of a plan to cool temperatures by expanding Sydney's tree canopy.
SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT. JS006 is a recombinant humanized IgG4κ monoclonal antibody against human TIGIT specifically, developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway. TIGIT (T cell immunoglobulin and ITIM domain) is an important inhibitory receptor expressed by NK cells and T cells, which can be engaged and activated by PVR family ligands highly expressed on tumor cells and suppressive immune cells to directly inhibit the killing effect of NK cells and T cells on tumor cells. A number of pre-clinical and clinical studies showed that activation of TIGIT pathway could be a crucial underlying mechanism for the resistance to PD-1 blockade therapy. Combination of TIGIT and PD-1/PD-L1 antibodies also showed a synergistic potential to enhance antitumor response to overcome anti-PD-1 resistance and broaden the beneficial population to immunotherapy.About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 26 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company to obtain marketing approval for PD-1 monoclonal antibody in China and clinical trial application approval for PCSK9 monoclonal antibody from the NMPA. The world’s first-in-human, first-in-class BTLA blocking antibody for solid tumors is currently in phase I clinical trials in the US and China. In early 2020, Junshi Biosciences joined forces with Institute of Microbiology Chinese Academy of Science to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences have about 2,000 full time employees in the United States and China, including research and development centers in San Francisco, Maryland, Shanghai, Suzhou, Beijing and Guangzhou. For more information, please visit: http://junshipharma.com.Contact Information IR Team: Junshi Biosciences firstname.lastname@example.org \+ 86 021-2250 0300 Solebury Trout Bob Ai email@example.com \+ 1 646.378-2926 PR Team: Junshi Biosciences Zhi Li firstname.lastname@example.org \+ 86 021-6105 8800
HAMILTON, Bermuda, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Enstar Group Limited (NASDAQ: ESGR) (“Enstar”) today announced that it has completed the sale and recapitalization of StarStone U.S. Holdings, Inc. (“StarStone U.S.”) through the sale of StarStone U.S to Core Specialty Insurance Holdings, Inc. (“Core Specialty”) in exchange for a combination of cash and approximately 25% of the shares in Core Specialty. Completion of the transaction followed receipt of regulatory approvals and satisfaction of various other closing conditions. Investors in Core Specialty, including SkyKnight Capital, L.P., Dragoneer Investment Group, Aquiline Capital Partners LLC and other investors, principally management and directors, have committed $610 million in new equity capital. Together with the rollover of Enstar’s existing ownership and an additional equity commitment of over $60 million from management and other investors, the equity capitalization of the company will increase to over $900 million.In connection with Enstar’s contribution of StarStone U.S. to Core Specialty, one of Enstar’s wholly owned subsidiaries has entered into a combination loss portfolio and adverse development cover reinsurance agreement with respect to StarStone U.S.’ legacy reserves.Pursuant to the terms of a recapitalization agreement entered into in August 2020, Enstar will acquire all of Trident V, L.P. and its affiliated funds’ (the “Trident V Funds’”) interest in Core Specialty in exchange for the majority of Enstar’s indirect interest in Northshore Holdings Ltd., the holding company for Atrium. The exchange transaction is subject to obtaining customary regulatory approvals and closing conditions and is expected to close in the first half of 2021.About EnstarEnstar is a NASDAQ-listed leading global insurance group that offers innovative capital release solutions through its network of group companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia, and other international locations. A market leader in completing legacy acquisitions, Enstar has acquired over 100 companies and portfolios since its formation in 2001. For further information about Enstar, see www.enstargroup.com.About Core SpecialtyCore Specialty offers a diversified range of property and casualty insurance products for small to mid-sized businesses. From eight underwriting offices spanning the U.S., the Company focuses on niche markets, local distribution, and superior underwriting knowledge, offering traditional as well as innovative insurance solutions to meet the needs of its customers and brokers. Core Specialty is an insurance holding company operating through StarStone Specialty Insurance Company, a U.S. excess and surplus lines insurer, and StarStone National Insurance Company, a U.S. admitted markets insurer. The Company is rated A- (Excellent) by A.M. Best. For further information about Core Specialty, please visit www.corespecialty.com.Cautionary StatementThis press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the intent, belief or current expectations of Enstar and its management team. Investors are cautioned that any such forward-looking statements speak only as of the date they are made, are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. In particular, Enstar and the Trident Funds may not be able to complete the referenced exchange transaction on the terms summarized above or other acceptable terms, or at all, due to a number of factors, including but not limited to the failure to obtain regulatory approvals or to satisfy other closing conditions. Important risk factors regarding Enstar can be found under the heading "Risk Factors" in Enstar’s Form 10-K for the year ended December 31, 2019 and in Enstar’s Form 10-Q for the three and nine months ended September 30, 2020 and are incorporated herein by reference. Furthermore, Enstar undertakes no obligation to update any written or oral forward-looking statements or publicly announce any updates or revisions to any of the forward-looking statements contained herein, to reflect any change in its expectations with regard thereto or any change in events, conditions, circumstances or assumptions underlying such statements, except as required by law.Contact: Enstar Communications Telephone: +1 (441) 292-3645
Prime Minister Scott Morrison is under renewed pressure from Pacific Island leaders to take greater action on climate change ahead of a global summit next week.
Monday was a good day to be a shareholder in either S&P Global (NYSE: SPGI) or IHS Markit (NYSE: INFO), with the former closing 3% higher and the latter 7.4%. This will be done with an all-stock transaction in which IHS Markit stockholders will receive 0.2838 shares of S&P Global for every share they currently own. All told, S&P Global and IHS Markit estimate the enterprise value of the deal at $44 billion, which includes $4.8 billion in net debt.